🇺🇸 FDA
Patent

US 10231983

Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

granted A61KA61K31/567A61K31/585

Quick answer

US patent 10231983 (Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients) held by Corcept Therapeutics Incorporated expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/567, A61K31/585, A61P, A61P3/10